Augmenix

Category Archives

Augmenix Announces Clearance of SpaceOAR® System

Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced Read more...

Augmenix aims for profitability with $10.8M Series D round as Varian acquisition option expires

Protecting patients from unnecessary exposure to radiation is the aim of start-up Augmenix. To advance its efforts and achieve profitability, the company Read more...

Augmenix Announces Completion of Series D Financing

Augmenix Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy today announced Read more...

Augmenix Receives CE Mark Approval for TraceIT® Fiducial Marker and TraceIT® Gel System

Augmenix, Inc. today announced that it has received European commercial approval for both TraceIT Fiducial Marker and TraceIT Gel System, absorbable markers Read more...

Augmenix Receives FDA Clearance to Market its TraceIT™ Tissue Marker

Augmenix, Inc., an innovative medical technology company focused on utilizing hydrogel technology in the fields of tissue marking and radiation oncology, Read more...

Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix

Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix Agreement creates opportunity for improving outcomes in radiation Read more...

Augmenix Announces First Commercial Use of SpaceOAR™ System for Prostate-Rectum Separation in Prostate Cancer Patients Undergoing Radiation Therapy

Augmenix Announces First Commercial Use of SpaceOAR™ System for Prostate-Rectum Separation in Prostate Cancer Patients Undergoing Radiation Therapy WALTHAM, Read more...

Augmenix, Inc. Closes $6.1 Million Financing

WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Augmenix announced today that it has closed a $6.1 million Series B financing. The round was led by Ascension Read more...

Page 2 of 212

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184